Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01034553 · OUTCOME

Progression-free Survival

Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma · Source last updated 2016-05-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
95% Confidence Interval
Time frame
Every 28 day cycle(up to 10 cycles) then follow-up for up to 2 years

Analysis population: All patients that received treatment were evaluated.

Groups in this outcome

All Patients

Patients receive oral aurora A kinase inhibitor MLN8237 once daily on days 1-14 and bortezomib IV on days 1, 4, 8 and 11. \> \> Aurora A kinase inhibitor MLN8237: Given orally \> \> bortezomib: Given IV

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
All Patients26

Reported measurements

Source class 1
Values in Months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
All Patients5.9Not reported4.115.8Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        4.1
        upper Limit
        15.8
        value
        5.9
denoms
  1. counts
    1. group Id
      OG000
      value
      26
    units
    Participants
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients receive oral aurora A kinase inhibitor MLN8237 once daily on days 1-14 and bortezomib IV on days 1, 4, 8 and 11. \> \> Aurora A kinase inhibitor MLN8237: Given orally \> \> bortezomib: Given IV
    id
    OG000
    title
    All Patients
param Type
MEDIAN
population Description
All patients that received treatment were evaluated.
reporting Status
POSTED
time Frame
Every 28 day cycle(up to 10 cycles) then follow-up for up to 2 years
title
Progression-free Survival
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice